Drugs /

auranofin

Back to Drugs List

Overview

NCI Definition [1]:
An orally available, lipophilic, organogold compound, used to treat rheumatoid arthritis, with anti-inflammatory and potential antineoplastic activities. Auranofin interacts with selenocysteine residue within the redox-active domain of mitochondrial thioredoxin reductase (TrxR), thereby blocking the activity of TrxR. As a result, this agent induces mitochondrial oxidative stress leading to the induction of apoptosis. Furthermore, this agent strongly inhibits the JAK1/STAT3 signal transduction pathway, thereby suppressing expression of immune factors involved in inflammation. TrxR, overexpressed in many cancer cell types, inhibits apoptosis, promotes cell growth and survival and plays a role in resistance to chemotherapy; TrxR catalyzes the reduction of oxidized thioredoxin (Trx) and plays a central role in regulating cellular redox homeostasis.

Clinical Trials

View Clinical Trials for auranofin

Auranofin has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating auranofin, 1 is phase 1/phase 2 (1 open).

HRAS G12R, HRAS G12V, and HRAS G13C are the most frequent biomarker inclusion criteria for auranofin clinical trials.

Lung adenocarcinoma, small cell lung carcinoma, and squamous cell lung carcinoma are the most common diseases being investigated in auranofin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Auranofin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating auranofin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
34031-32-8, auranofin, gold, (1-thio-beta-d-glucopyranose 2,3,4,6-tetraacetato-s)(triethylphosphine)-, auranofin (product), triethylphosphine gold, 2,3,4,6-tetra-o-acetyl-1-thio-beta-d-glucopyranosato-s (triethylphosphine)gold, auranofin, (1-thio-beta-d-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate, auranofinum, auranofin [chemical/ingredient], auranofin (substance), auranofine, auroafen, auranofina, ridaura
NCIT ID [1]:
C65242
SNOMED ID [1]:
C-14602

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.